Invivyd Inc. has reported its financial results for the first quarter of 2025, detailing a net product revenue for PEMGARDA™ (pemivibart) of $11.3 million. This reflects a decrease from the $13.8 million reported in Q4 2024, attributed to a planned transition from a contracted to an internalized sales force. However, the company has observed a re-acceleration of PEMGARDA revenue in the second quarter of 2025 to date. Invivyd reported a net loss of $16.3 million for Q1 2025, an improvement compared to a net loss of $43.5 million in the same period of 2024. The basic and diluted net loss per share was $0.14 for Q1 2025, compared to $0.38 for the comparable period in 2024. The company maintains a cash position of $48.1 million as of March 31, 2025, and has secured a $30 million non-dilutive term loan facility with Silicon Valley Bank to support its financial strategy. Invivyd is targeting near-term profitability by the end of the first half of 2025, supported by anticipated growth in net product revenue and continued reduction of operating expenses. In terms of business operations, Invivyd continues to enhance the uptake of PEMGARDA among healthcare providers treating immunocompromised patients, supported by their internal sales team. The company is also anticipating the Phase 1 clinical trial data read-out of VYD2311, which will include potency, half-life, and full safety unblinding later in the second quarter of 2025.